Abstract:Importance: There are conflicting results claiming that Alzheimer disease signature neurodegeneration may be more, less, or similarly advanced in individuals with β-amyloid peptide (Aβ)-negative (Aβ-) suspected non-Alzheimer disease pathophysiology (SNAP) than in Aβ-positive (Aβ+) counterparts.Objective: To examine patterns of neurodegeneration in individuals with SNAP compared with their Aβ+ counterparts.Design, Setting, and Participants: A longitudinal cohort study was conducted among individuals with mild cognitive impairment (MCI) and cognitively normal individuals receiving care at Alzheimer's Disease Neuroimaging Initiative sites in the United States and Canada for a mean follow-up period of 30.5 months from August 1, 2005, to June 30, 2015. Several neurodegeneration biomarkers and longitudinal cognitive function were compared between patients with distinct SNAP (Aβ- and neurodegeneration-positive [Aβ-N+]) subtypes and their Aβ+N+ counterparts.Main Outcomes and Measures: Participants were classified according to the results of their florbetapir F-18 (Aβ) positron emission tomography and their Alzheimer disease-associated neurodegeneration status (temporoparietal glucose metabolism determined by fluorodeoxyglucose F 18 [FDG]-labeled positron emission tomography and/or hippocampal volume [HV] determined by magnetic resonance imaging: participants with subthreshold HV values were regarded as exhibiting hippocampal volume atrophy [HV+], while subthreshold mean FDG values were considered as FDG hypometabolism [FDG+]).Results: The study comprised 265 cognitively normal individuals (135 women and 130 men; mean [SD] age, 75.5 [6.7] years) and 522 patients with MCI (225 women and 297 men; mean [SD] age, 72.6 [7.8] years). A total of 469 individuals with MCI had data on neurodegeneration biomarkers; of these patients, 107 were Aβ-N+ (22.8%; 63 FDG+, 82 HV+, and 38 FDG+HV+) and 187 were Aβ+N+ (39.9%; 135 FDG+, 147 HV+, and 95 FDG+HV+ cases). A total of 209 cognitively normal participants had data on neurodegeneration biomarkers; of these, 52 were Aβ-N+ (24.9%; 30 FDG+, 33 HV+, and 11 FDG+HV+) and 37 were Aβ+N+ (17.7%; 22 FDG+, 26 HV+, and 11 FDG+HV+). Compared with their Aβ+ counterparts, all patients with MCI SNAP subtypes displayed better preservation of temporoparietal FDG metabolism (mean [SD] FDG: Aβ-N+, 1.25 [0.11] vs Aβ+N+, 1.19 [0.11]), less severe atrophy of the lateral temporal lobe, and lower mean (SD) cerebrospinal fluid levels of tau (59.2 [32.8] vs 111.3 [56.4]). In MCI with SNAP, sustained glucose metabolism and gray matter volume were associated with disproportionately low APOE ε4 (Aβ-N+, 18.7% vs Aβ+N+, 70.6%) and disproportionately high APOE ε2 (18.7% vs 4.8%) carrier prevalence. Slower cognitive decline and lower rates of progression to Alzheimer disease (Aβ-N+, 6.5% vs Aβ+N+, 32.6%) were also seen in patients with MCI with SNAP subtypes compared with their Aβ+ counterparts. In cognitively normal individuals, neurodegeneration biomarkers did not differ between Aβ-N+ and Aβ+N+ cases.Conclusions and Relevance: In MCI with SNAP, low APOE ε4 and high APOE ε2 carrier prevalence may account for differences in neurodegeneration patterns between Aβ-N+ and Aβ+N+ cases independent from the neuroimaging biomarker modality used to define neurodegeneration associated with Alzheimer disease.

Distinct Brain Functional Impairment Patterns Between Suspected Non-Alzheimer Disease Pathophysiology and Alzheimer’s Disease: A Study Combining Static and Dynamic Functional Magnetic Resonance Imaging

Temporal Dynamic Changes of Intrinsic Brain Activity Associated with Cognitive Reserve in Prodromal Alzheimer's Disease.

Distinct Spontaneous Brain Activity Patterns in Different Biologically-Defined Alzheimer's Disease Cognitive Stage: A Preliminary Study.

Altered Functional Connectivity Pattern of Hippocampal Subfields in Individuals with Objectively-Defined Subtle Cognitive Decline and Its Association with Cognition and Cerebrospinal Fluid Biomarkers

Disease Trajectories in Elders with Suspected Non-Alzheimer's Pathophysiology and Its Comparison with Alzheimer's Disease Pathophysiology: a Longitudinal Study.

Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease

Atrophy, hypometabolism and implication regarding pathology in late-life major depression with suspected non-Alzheimer pathophysiology (SNAP)

Alteration of Functional Connectivity Network in Population of Objectively-Defined Subtle Cognitive Decline.

Distinct Impaired Patterns of Intrinsic Functional Network Centrality in Patients with Early- and Late-Onset Alzheimer’s Disease

Distinct Patterns of Interhemispheric Connectivity in Patients with Early- and Late-Onset Alzheimer’s Disease

The clinical importance of suspected non-Alzheimer disease pathophysiology

Altered Spontaneous Brain Activity in Subjects with Different Cognitive States of Biologically Defined Alzheimer's Disease: A Surface-Based Functional Brain Imaging Study

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non–Alzheimer Disease Pathophysiology

Disrupted Regional Cerebral Blood Flow, Functional Activity and Connectivity in Alzheimer’s Disease: A Combined ASL Perfusion and Resting State fMRI Study

Abnormal Dynamic Functional Networks in Subjective Cognitive Decline and Alzheimer's Disease

Disrupted Regional Cerebral Blood Flow, Functional Activity and Connectivity in Alzheimer's Disease: A Combined ASL Perfusion and Resting State Fmri Study.

Grab‐AD: Generalizability and Reproducibility of Altered Brain Activity and Diagnostic Classification in Alzheimer's Disease

Functional and structural alterations of dorsal attention network in preclinical and early-stage Alzheimer's disease

Changes of intranetwork and internetwork functional connectivity in Alzheimer's disease and mild cognitive impairment.

Spatial and Temporal Patterns of Cortical Mean Diffusivity in Alzheimer's Disease and Suspected Non-Alzheimer's Disease Pathophysiology

A Multimodal Meta-Analytical Evidence of Functional and Structural Brain Abnormalities Across Alzheimer's Disease Spectrum